Alzheimer’s Therapeutic Research Institute
About the Institute
The Alzheimer’s Therapeutic Research Institute (ATRI) of the Keck School of Medicine of USC is an academic institute comprised of an unmatched group of expert scientific collaborators committed to advancing the development of new treatments for Alzheimer’s disease (AD) through innovation in clinical trials.
Located in San Diego, the institute is an integral part of the Keck School of Medicine of USC’s mission to create a leading hub of basic, translational and clinical research in neuroscience and neurological diseases by collaborating with sites and investigators around the world. USC ATRI promotes extensive collaboration and data sharing across academia, industry, regulators and advocacy groups with a focus on training future leaders in AD clinical research.
USC ATRI is funded by the National Institutes of Health (NIH), the Alzheimer’s Association, the Department of Defense, the pharmaceutical partners and advocacy groups to develop novel methods and engage in all phases of AD clinical trials as well as observational studies. Bringing broad expertise to a comprehensive array of partners, USC ATRI manages a portfolio of national and international multi-site studies.
Learn more about ATRI
Neurologist Paul Aisen works to stop Alzheimer’s before it startsThe researcher explains five things to know about the only disease among the top 10 in America that cannot be prevented, cured or slowed Scientists at the Alzheimer’s Therapeutic Research Institute (ATRI) of the Keck School of Medicine of USC have enrolled more than 1,000 people in their international clinical trials and are still seeking more participants.
View All ATRI Events